Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Regulation of SGK1-mediated Pathological Cardiac Hypertrophy by Non-Canonical ERAD

Award Number: F31HL172675
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 12/01/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Regulation of SGK1-mediated Pathological Cardiac Hypertrophy by Non-Canonical ERAD - Project Summary: Heart disease is the leading cause of mortality and is often preceded by pathological cardiac hypertrophy due to chronic hypertension and sustained increases in cardiac afterload. While initially an adaptive response to maintain cardiac output and systemic blood supply, pathological cardiac hypertrophy eventually leads to a decompensated state of heart failure (HF). The initial adaptive aspect of hypertrophic growth requires increases in protein synthesis, which must be balanced by adequate protein folding, and degradation of misfolded, potentially toxic proteins. Without this balance, cardiac myocytes cannot maintain protein homeostasis, or proteostasis, which threatens functional cellular integrity and viability. The endoplasmic reticulum (ER) is a central node in proteostasis, with ~40% of proteins trafficked through this organelle, underscoring the importance of ER proteostasis in the heart. An important feature of ER proteostasis is recognition and degradation of terminally misfolded proteins through ER associated degradation (ERAD). While ERAD canonically recognizes misfolded ER proteins, we have recently identified the first and only described non-ER substrate for ERAD, serum/glucocorticoid regulated kinase 1 (SGK1), a pro-growth, cytosolic (non-ER) kinase. Intriguingly, SGK1 is not misfolded, yet is targeted to the cytosolic face of the ER for proteasome- mediated degradation via ERAD and requires the ER E3 ubiquitin ligase, HRD1. Further, we have found that SGK1 degradation by ERAD is impaired in human hypertrophic heart failure and in a mouse model of pressure overload-induced heart failure. SGK1 promotes growth in cancer cells, and our work and others’ have demonstrated relevance for SGK1 in cardiac pathology, but none have investigated whether SGK1 is required for the development of pathological cardiac hypertrophy and if this is mediated by impairing its degradation at the ER via ERAD. Our hypothesis is that the cytosolic kinase, SGK1, drives pathological cardiac hypertrophy in the pressure-overloaded heart and that inhibiting SGK1 ubiquitylation at the ER slows its degradation by proteasomes, which increases SGK1 levels and enhances its pro-hypertrophic effects in the heart. We will address this hypothesis using primary cultured cardiac myocytes and mice subjected to pressure overload in the following specific aims: (1) Determine the effects of depleting endogenous SGK1 on cardiac myocyte hypertrophy; and (2) Examine the effects on cardiac myocyte hypertrophy of ectopically expressed wild type SGK1, or a degradation resistant mutant form of SGK1 that cannot be ubiquitylated but retains ER localization. Pursuit of these aims will determine whether SGK1 is a promising target in mitigating pathological cardiac hypertrophy and whether SGK1 degradation by non-canonical ERAD is an important mechanistic aspect of cardiac pathophysiology that can be modulated therapeutically.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $41,731 )
2026	2026	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Cardiovascular Diseases Research	000	2	5/8/2026	NON-COMPETING CONTINUATION	$41,731
														Subtotal = $41,731

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Cardiovascular Diseases Research	001	1	12/25/2024	NEW	$0
2025	2024	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Cardiovascular Diseases Research	000	1	12/25/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $40,591 )
2024	2024	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Cardiovascular Diseases Research	000	1	8/21/2024	NEW	$40,591
														Subtotal = $40,591

Grand Total All Awards = $82,322

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Regulation of SGK1-mediated Pathological Cardiac Hypertrophy by Non-Canonical ERAD

Award Number: F31HL172675

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 12/01/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer